BBIO Stock Cash Flow Statements

BridgeBio Pharma Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

BridgeBio Pharma Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30

operating activities:
net income	-183,758,000	-169,608,000	-267,389,000	-164,254,000	-75,544,000	-36,160,000	-170,328,000	-179,488,000	-160,703,000	-142,732,000	-140,570,000	-140,193,000	-2,559,000	-201,330,000	-152,282,000	-161,016,000	-102,074,000	-171,082,000	-135,025,000	-130,167,000	-136,214,000	-104,082,000	-84,151,000	-60,733,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation	37,241,000	25,882,000	30,127,000	27,162,000	21,454,000	17,057,000	37,025,000	22,600,000	27,178,000	21,907,000	21,789,000	17,361,000	28,287,000	24,122,000	19,774,000	16,042,000	30,112,000	33,577,000	12,146,000	17,699,000	18,392,000	10,222,000
losses on extinguishments of debt
accretion of debt	27,465,000	25,641,000	10,364,000	1,716,000	1,668,000	2,015,000	2,183,000	2,144,000	2,242,000	2,338,000	2,101,000	2,086,000	1,900,000	2,483,000	1,752,000	1,390,000	1,404,000	1,249,000
depreciation and amortization	1,317,000	1,284,000	1,367,000	1,538,000	1,574,000	1,596,000	1,585,000	1,639,000	1,637,000	1,633,000	1,660,000	1,645,000	1,582,000	1,884,000	1,526,000	265,000								374,000
noncash lease expense	1,236,000	994,000	991,000	1,026,000	1,024,000	1,069,000	1,008,000	1,000,000	992,000	1,032,000				1,545,000	1,533,000
net income from equity method investments	20,189,000	15,556,000	16,695,000
gain on deconsolidation of a subsidiary
gain from investment in equity securities			0	0	0	-8,136,000				-964,000
dividend from investment in equity securities
other noncash adjustments	-1,491,000	-3,973,000	-697,000	-148,000	-3,542,000	1,631,000	565,000	-56,000	-125,000	-203,000	-4,083,000	945,000	3,138,000	604,000	-1,421,000	1,307,000	2,110,000	5,096,000	-4,643,000	4,844,000	1,446,000	1,034,000
changes in operating assets and liabilities:
accounts receivable	38,397,000	-110,543,000
inventories	-13,389,000	-3,193,000
prepaid expenses and other current assets	-22,258,000	-487,000	3,625,000	-11,037,000	-3,161,000	-3,345,000	-1,722,000	-2,037,000	4,599,000	-3,542,000	3,599,000	7,093,000	-364,000	-2,657,000	-519,000	-5,143,000	-48,000	1,448,000	-1,668,000	-7,025,000	-1,212,000	2,846,000	-951,000	-9,196,000
other assets	-1,761,000	1,587,000	1,970,000	-1,370,000	498,000	444,000	-2,989,000	1,411,000	515,000	-483,000	876,000	1,404,000	790,000	7,901,000	-886,000	-3,207,000	390,000	-6,113,000	-1,952,000	771,000	-231,000	-734,000	-15,265,000	413,000
accounts payable	-1,055,000	17,571,000	-3,745,000	-3,601,000	14,785,000	-5,927,000	6,184,000	694,000	-298,000	-3,800,000	1,376,000	1,365,000	-1,276,000	-1,814,000	1,473,000	-11,665,000	11,233,000	1,792,000	-1,282,000	-3,436,000	-251,000	4,234,000	-1,418,000	-3,385,000
accrued compensation and benefits	3,726,000	-19,363,000	11,406,000	13,958,000	6,591,000	-14,969,000	11,958,000	6,915,000	7,298,000	-18,369,000	6,760,000	280,000	7,474,000	-16,876,000	11,821,000	4,051,000	4,487,000	-12,981,000	6,194,000	4,446,000	5,619,000	-7,670,000	5,737,000	2,844,000
accrued research and development liabilities	-2,335,000	-642,000	-6,725,000	8,387,000	-4,101,000	11,168,000	689,000	778,000	-8,766,000	-2,556,000	-4,761,000	-5,501,000	6,771,000	-818,000	6,492,000	2,223,000	-3,671,000	6,134,000	2,166,000	-12,341,000	7,719,000	8,626,000	7,697,000	3,779,000
operating lease liabilities	-1,647,000	-1,470,000	-1,443,000	-1,478,000	-1,386,000	-1,595,000	-1,158,000	-1,228,000	-1,193,000	-1,250,000	-1,426,000	-1,471,000	-1,528,000	-1,820,000	-1,648,000	-1,698,000	-1,438,000	-1,338,000	-1,163,000	-891,000	-862,000	-556,000
deferred revenue	-3,920,000	-2,571,000	1,300,000	-1,661,000	-1,788,000	24,024,000	-974,000	-1,280,000	-1,436,000	-1,748,000	-1,707,000	328,000
other current liabilities	23,664,000	2,945,000
net cash from operating activities	-80,681,000	-199,235,000	-195,326,000	-180,566,000	74,703,000	-219,537,000	-124,819,000	-145,226,000	-113,353,000	-144,322,000	-93,243,000	-135,163,000	-30,453,000	-160,635,000	-133,895,000	-121,561,000	-91,713,000	-150,765,000	-96,261,000	-131,684,000	-87,849,000	-83,920,000	-76,203,000	-49,996,000
capex	0	0	-47,000	-137,000	-54,000	-695,000	-435,000	-431,000	-428,000	-12,000	-801,000	-759,000	-2,402,000	-859,000	-2,536,000	-6,462,000	-2,287,000	-1,961,000	-2,146,000	-549,000	-346,000	-4,477,000	-1,747,000	-381,000
free cash flows	-80,681,000	-199,235,000	-195,373,000	-180,703,000	74,649,000	-220,232,000	-125,254,000	-145,657,000	-113,781,000	-144,334,000	-94,044,000	-135,922,000	-32,855,000	-161,494,000	-136,431,000	-128,023,000	-94,000,000	-152,726,000	-98,407,000	-132,233,000	-88,195,000	-88,397,000	-77,950,000	-50,377,000
investing activities:
purchases of marketable securities			0	0	-49,416,000	-44,395,000	0	-9,972,000			-2,858,000	-15,024,000	-63,889,000	-55,722,000	-14,414,000	-65,544,000	-130,643,000	-379,291,000	-18,050,000	-101,001,000			-15,154,000
maturities of marketable securities			0	40,000,000			0	41,000,000	23,550,000	18,000,000	26,869,000	158,900,000	107,224,000	186,695,000	75,000,000	66,266,000	139,734,000	99,200,000	110,121,000	56,500,000	40,016,000	42,500,000
purchases of investments in equity securities			0	0	0	-20,271,000
proceeds from sales of investments in equity securities			0	0	0	63,229,000
proceeds from special cash dividends received from an investment in equity securities
payment for intangible assets
purchases of property and equipment			-47,000	-137,000	-54,000	-695,000	-435,000	-431,000	-428,000	-12,000	-801,000	-759,000	-2,402,000	-859,000	-2,536,000	-6,462,000	-2,287,000	-1,961,000	-2,146,000	-549,000	-346,000	-4,477,000	-1,747,000	-381,000
decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries			0	-42,000
net cash from investing activities	-13,002,000	-1,595,000	-3,237,000	38,226,000	3,039,000	22,753,000	-66,000	37,682,000	4,119,000	12,298,000	17,965,000	146,857,000	149,702,000	138,623,000	21,800,000	58,968,000	458,000	-282,052,000	83,018,000	-45,050,000	-128,984,000	38,023,000	-16,901,000	-197,342,000
financing activities:
proceeds from issuance of 2031 notes	0	575,000,000
issuance costs and discounts associated with 2031 notes	0	-12,034,000
repurchase of common stock	0	-48,276,000															-5,308,000	-50,000,000	0	0	0	-75,000,000
proceeds from royalty obligation under royalty purchase agreement
issuance costs associated with royalty obligation under royalty purchase agreement
proceeds from term loan under amended financing agreement
issuance costs and discounts associated with term loan under amended financing agreement
repayment of term loans	0	-459,000,000
repayment of deferred royalty obligation	-1,861,000	-144,000
proceeds from issuance of common stock through public offerings			0	-18,000	-495,000	315,254,000
proceeds from common stock issuances under espp
proceeds from stock option exercises, net of repurchases	7,159,000	2,521,000	2,848,000	30,000	241,000	537,000	786,000	4,910,000	119,000	193,000	57,000	449,000	56,000	104,000	2,349,000	3,078,000	3,752,000	7,464,000	10,002,000	820,000	1,367,000	734,000
transactions with noncontrolling interests	750,000	800,000					-2,301,000									3,430,000
repurchase of rsu shares to satisfy tax withholding	-1,995,000	-1,776,000	-1,404,000	-1,443,000	-1,743,000	-2,936,000
net cash from financing activities	302,041,000	60,328,000	473,931,000	707,000	-5,729,000	279,548,000	-4,523,000	307,040,000	-1,231,000	150,249,000	6,377,000	1,445,000	-20,796,000	-160,000	325,381,000	-135,456,000	-1,391,000	547,912,000	4,531,000	2,782,000	703,000	439,173,000	42,904,000	367,508,000
net increase in cash, cash equivalents and restricted cash	208,358,000	-140,502,000	275,368,000	-141,633,000	72,013,000	82,764,000	-129,408,000	199,496,000	-110,465,000	18,225,000	-68,901,000	13,139,000	98,453,000	-22,172,000	213,286,000	-198,049,000	-92,646,000	115,095,000	-8,712,000	-173,952,000	-216,130,000	393,276,000	-50,200,000	120,170,000
cash, cash equivalents and restricted cash at beginning of period	0	683,244,000		0	0	394,732,000	0	0	0	416,884,000		0	0	396,365,000	0	0	0	358,679,000	0	0	0	364,197,000	0	0
cash, cash equivalents and restricted cash at end of period	208,358,000	542,742,000		-141,633,000	72,013,000	477,496,000	-129,408,000	199,496,000	-110,465,000	435,109,000		13,139,000	98,453,000	374,193,000	213,286,000	-198,049,000	-92,646,000	473,774,000	-8,712,000	-173,952,000	-216,130,000	757,473,000	-50,200,000	120,170,000
loss on extinguishment of debt		21,155,000	0	0	0	26,590,000
proceeds from special cash dividends received from investments in equity securities			0	0	0	25,682,000
payment for an intangible asset		-1,595,000	-3,190,000	-1,595,000	-2,393,000	-797,000						0
proceeds from bridgebio common stock issuances under espp		3,237,000	0	2,138,000	0	2,364,000	1,000	1,588,000	0	1,809,000		1,592,000	0	966,000	0	2,169,000	0	1,652,000
accrual of payment-in-kind interest on term loan							3,465,000	0	3,403,000	3,339,000
gain on deconsolidation of subsidiaries			0	-52,027,000
fair value of shares issued under a license agreement												0
loss on sale of certain assets											0	0	0	6,261,000
impairment of long-lived assets											0	67,000	0	12,653,000
gain from sale of priority review voucher, excluding transaction costs											0	0
gain from recognition of receivable from licensing and collaboration agreement											0	0	0	-12,500,000
accrued professional and other liabilities			10,801,000	-5,522,000	166,000	-1,256,000	6,572,000	-7,385,000
proceeds from sale of priority review voucher												0
proceeds from sale of certain assets											0	0	0	10,000,000
proceeds from royalty obligation under funding agreement
issuance costs and discounts associated with royalty obligation under funding agreement
other financing activities									-1,180,000	5,743,000
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
receivables from licensing and collaboration agreements				182,000	234,834,000	-233,743,000
proceeds from term loan under financing agreement				0	0	450,000,000
issuance costs and discounts associated with term loan under financing agreement				0	-3,732,000	-12,254,000
repayment of term loan under loan and security agreement				0	0	-473,417,000
net income from equity method investment
fair value adjustment of warrants							-1,036,000	274,000	-111,000	-111,000	125,000	56,000	538,000	852,000
loss on deconsolidation of pellepharm							0	0	0	1,241,000
decrease in cash and cash equivalents resulting from deconsolidation of pellepharm							0	0	0	-503,000
(gain) income from investment in equity securities
leo call option income																		-5,550,000
loss on early extinguishment of debt
receivable from licensing and collaboration agreements							3,419,000	3,443,000	2,148,000	6,318,000	16,001,000	-3,825,000	-7,273,000	10,266,000	-12,039,000	27,653,000
sales of marketable securities															-36,234,000
purchases of investment in equity securities							-29,224,000	-6,810,000	-24,030,000	-47,474,000	-29,250,000	-15,382,000	-2,768,000	-8,162,000	-29,423,000
sales of investment in equity securities							29,593,000	13,895,000	24,781,000	42,287,000	24,005,000	19,122,000	3,037,000	6,671,000	29,407,000
increase in cash and cash equivalents from consolidation of pellepharm															0	0
proceeds from issuance of common stock through private placement offering							-454,000
proceeds from issuance of common stock through follow-on offering							0	0	1,033,000	143,016,000
proceeds from issuance of common stock through atm offering							0
proceeds from issuance of 2029 notes
issuance costs and discounts associated with issuance of 2029 notes
purchase of capped calls															0	0	0	-61,295,000	0	0	0	-49,280,000
repurchases of common stock
repurchase of eidos noncontrolling interest, including direct transaction costs															0	-250,000	-4,516,000	-80,324,000
proceeds from term loan, net of issuance costs
repayment of term loan											0	0				0
income from investment in equity securities
repurchase of shares to satisfy tax withholding								-2,610,000	-1,203,000	-512,000		-596,000	-366,000	-110,000	-711,000	-733,000	-2,281,000	-1,021,000	-471,000
issuance costs associated with term loan												0	0	-1,120,000
accrued professional services										2,225,000	-2,440,000	-1,954,000	772,000	-1,374,000	1,811,000	-1,153,000	1,859,000	-360,000	1,256,000	-5,237,000	5,465,000	923,000
other accrued and other long-term liabilities										-8,597,000	-6,530,000	-4,590,000	11,270,000	-2,883,000	13,636,000
operating activities
net gain from investment in equity securities
fair value of shares issued under license agreements
leo call option expense															0	0			352,000	-78,000	1,737,000	-539,000	57,000	-276,000
acquired in-process research and development assets																							0	1,060,000
receivable from a related party																8,500,000	-8,500,000	-462,000	8,000,000
investing activities
proceeds from sale of priority review voucher, excluding transaction costs
other investing activities
financing activities
proceeds from issuance of 2029 notes in 2021 and 2027 notes in 2020															0	0	0	747,500,000
issuance costs and discounts associated with issuance of 2029 notes and 2027 notes															0	0	0	-16,064,000
proceeds from issuance of noncontrolling interests
repurchase of common stock to satisfy tax withholding
proceeds from at-the-market issuance of noncontrolling interest by eidos																			0	0	0	24,094,000
proceeds from issuance of common stock through at-the-market offering
repurchase of noncontrolling interest																							0	-26,383,000
supplemental disclosures of cash flow information:
cash paid for interest															1,535,000	17,425,000	1,901,000	8,913,000	2,041,000	9,159,000	2,068,000	2,054,000	1,756,000	1,753,000
supplemental disclosures of non-cash investing and financing information:
payment-in-kind interest accrued in prior year added to principal of term loan
deferred merger transaction costs included in accounts payable and accrued professional services																			315,000
leasehold improvements paid by landlord															0
transfers from																				1,080,000	-3,109,000	11,601,000
recognition of property and equipment previously classified in other assets																			0	0	0	10,000,000
noncash contribution by a noncontrolling interest															0
unpaid property and equipment																		1,787,000
recognized intangible asset recorded in other accrued and other long-term liabilities
unpaid debt issuance costs
net noncash portion of repurchase of eidos noncontrolling interests															1,000	0	0	38,167,000
direct transaction costs in the repurchase of eidos recorded in additional paid-in capital previously classified in prepaid expenses and other current assets															0	0	0	8,749,000
reconciliation of cash, cash equivalents and restricted cash
cash and cash equivalents
restricted cash
restricted cash - included in other assets
total cash, cash equivalents and restricted cash at end of year
net income from investment in equity securities												-10,259,000	10,362,000	12,866,000
proceeds from term loan																0
net gains from investment in equity securities
share in net income of equity method investments
acquisition of intangible assets															0
others
proceeds from issuance of common stock in connection with initial public offering
proceeds from issuance of noncontrolling interest to alexion																							0
proceeds from term loans, net of issuance costs																							17,152,000	0
transfers
intangible assets recorded in other accrued and other long-term liabilities
build-to-suit funding liability accrual
fair value of success fee derivative at issuance of eidos term loan
proceeds from disposal of property and equipment																			0	0
supplemental disclosures of noncash investing and financing information:
recognized intangible asset recorded in other accrued liabilities and other long-term liabilities
repurchase of common stock recorded in accounts payable
restricted cash — included in “prepaid expenses and other current assets”
restricted cash — included in “other assets”
total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows
other accrued and other liabilities																	6,139,000	-3,540,000	3,445,000	-449,000	5,324,000	15,000
investment in equity securities
noncash contribution by an nci
recognized intangible asset recorded in accrued research and development liabilities
leasehold improvement paid by landlord
transfers from noncontrolling interests																	-1,416,000	1,690,000
1.
amortization of operating lease right-of-use assets																		1,365,000
proceeds from issuance of redeemable convertible noncontrolling interests to third-party investors																			0	1,000,000	0	1,000,000
direct transaction costs in the repurchase of eidos noncontrolling interest included in accounts payable and accrued professional services																		4,766,000
issuance costs associated with issuance of 2027 notes included in other accrued and other liabilities																						664,000
gain on deconsolidation of pellepharm
change in fair value of lianbio warrants
fair value of equity method investment
accretion of 2027 notes and term loans																			5,422,000	5,335,000	5,219,000	1,761,000
change in fair value of eidos financial instruments
payments of merger transaction costs
cash paid for in-process research and development assets acquired																							0	0
cash and cash equivalents acquired in ml bio asset acquisition																							0
proceeds from issuance of common stock in connection with the initial public offering of bridgebio in 2019 and eidos in 2018, net of underwriting discounts and commissions
proceeds from issuance of 2027 notes																			0	0	0	550,000,000
issuance costs and discounts associated with issuance of 2027 notes																			0	0	-664,000	-12,375,000
proceeds from issuance of promissory notes
proceeds from repayment of nonrecourse notes																							0	0
proceeds from the issuance of redeemable convertible preferred units, net of issuance costs
proceeds from repayment of the loans received by noncontrolling interest shareholder
myokardia distributions																							0	0
tenant improvement paid by landlord																							1,138,000
non-cash contribution by a noncontrolling interest
conversion of redeemable noncontrolling interest into noncontrolling interest
conversion of promissory note into redeemable convertible noncontrolling interest
fair value of redeemable convertible noncontrolling interest issued for acquired in-process research and development assets
proceeds from issuance of common stock in connection with the initial public offering
operating lease right-of-use assets obtained in exchange for operating lease obligations																				0	2,419,000	9,395,000
payment of deferred offering costs
deferred offering costs included in accounts payable and other accrued liabilities
accretion of term loans and convertible promissory notes																							787,000	20,000
other accrued liabilities																							-1,162,000	2,184,000
other liabilities																							0	83,000
proceeds from issuance of common stock in connection with the initial public offering of the corporation in 2019 and eidos in 2018, net of underwriting discounts and commissions
proceeds from third-party investors in redeemable convertible noncontrolling interests																							0
proceeds from stock option exercises
conversion of promissory note upon issuance of series c redeemable convertible preferred units
capital transaction upon merger
net accretion and amortization of premium and discounts on marketable securities
equity-based compensation																								5,846,000
loss on disposal of property and equipment																								55,000
income from ml bio asset acquisition
income from pellepharm																								6,589,000
shares issued under license agreements																								0
proceeds from issuance of bridgebio pharma llc common stock equivalents, net of issuance costs
proceeds from issuance of common stock in connection with the initial public offering, net of underwriting discounts and commissions
proceeds from issuance of common stock in connection with the initial public offering of eidos, net of underwriting discounts and commissions
issuance of loan to noncontrolling interest shareholder
proceeds from subsidiary stock option exercises																								346,000
transfers to																								13,529,000
proceeds from the issuance of series c preferred units, net of issuance costs

We provide you with 20 years of cash flow statements for BridgeBio Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BridgeBio Pharma stock. Explore the full financial landscape of BridgeBio Pharma stock with our expertly curated income statements.

The information provided in this report about BridgeBio Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.